Reich N O, Ortiz de Montellano P R
Biochem Pharmacol. 1986 Apr 15;35(8):1227-33. doi: 10.1016/0006-2952(86)90264-9.
Clofibrate, an antilipidemic drug that acts by a still obscure mechanism, is known to specifically increase up to 30-fold the activity of the hepatic cytochrome P-450 isozyme that omega-hydroxlates lauric acid. The thesis that accelerated catabolism of medium-length fatty acids initiated by omega-hydroxylation contributes significantly to the antilipidemic action of clofibrate has been examined by measuring the impact on serum triglyceride levels of coadministering clofibrate and a suicide substrate that inactivates the hydroxylase. The results suggest that the antilipidemic action of clofibrate does not depend critically on the enhanced omega-hydroxylation of fatty acids.
氯贝丁酯是一种作用机制尚不清楚的抗脂药物，已知它能使催化月桂酸ω-羟化的肝细胞色素P-450同工酶的活性特异性增加高达30倍。有人提出，由ω-羟化引发的中链脂肪酸分解代谢加速对氯贝丁酯的抗脂作用有显著贡献，通过测量同时给予氯贝丁酯和一种使羟化酶失活的自杀性底物对血清甘油三酯水平的影响，对这一论点进行了研究。结果表明，氯贝丁酯的抗脂作用并不关键地依赖于脂肪酸ω-羟化作用的增强。
